This cohort study uses National Cancer Database data to investigate whether breast cancer with low ERBB2 expression is a clinically distinct subtype compared with breast cancer with no ERBB2 expression, with distinct epidemiological characteristics, prognosis, and response to neoadjuvant chemotherapy. Here, ERBB2 is linked to cancer.